HansBiomed Corporation (KOSDAQ:042520)

Market Cap	691.59B +522.8%
Revenue (ttm)	100.17B +24.2%
Net Income	-27.44B
EPS	-2,098.06
Shares Out	13.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,483
Average Volume	388,175
Open	51,000
Previous Close	50,500
Day's Range	49,550 - 52,100
52-Week Range	6,180 - 54,100
Beta	2.31
RSI	68.73
Earnings Date	Feb 12, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 277
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.